<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rmt</journal-id><journal-title-group><journal-title xml:lang="ru">Общая реаниматология</journal-title><trans-title-group xml:lang="en"><trans-title>General Reanimatology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1813-9779</issn><issn pub-type="epub">2411-7110</issn><publisher><publisher-name>FSBI "SRIGR" RAMS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15360/1813-9779-2025-5-2579</article-id><article-id custom-type="elpub" pub-id-type="custom">rmt-2579</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Прогностические маркеры функционального исхода при подтипах ишемического инсульта</article-title><trans-title-group xml:lang="en"><trans-title>Predictive Markers of Functional Outcome in Subtypes of Ischemic Stroke</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1743-4713</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тынтерова</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Tynterova</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анастасия Михайловна Тынтерова</p><p>236041, г. Калининград, ул. Александра Невского, д. 14</p></bio><bio xml:lang="en"><p>Anastasia M. Tynterova</p><p>14 Aleksandr Nevsky Str., 236041 Kaliningrad</p></bio><email xlink:type="simple">antynterova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4052-1604</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Моисеева</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Moiseeva</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Екатерина Михайловна Моисеева</p><p>236041, г. Калининград, ул. Александра Невского, д. 14</p></bio><bio xml:lang="en"><p>Ekaterina M. Moiseeva</p><p>14 Aleksandr Nevsky Str., 236041 Kaliningrad</p></bio><email xlink:type="simple">katerinamoiseeva898@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8056-2019</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хоймов</surname><given-names>М.  С. </given-names></name><name name-style="western" xml:lang="en"><surname>Khoymov</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Матвей Сергеевич Хоймов</p><p>236041, г. Калининград, ул. Александра Невского, д. 14</p></bio><bio xml:lang="en"><p>Matvey S. Khoymov</p><p>14 Aleksandr Nevsky Str., 236041 Kaliningrad</p></bio><email xlink:type="simple">matthewkhoimov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8848-6134</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шушарина</surname><given-names>Н.  Н. </given-names></name><name name-style="western" xml:lang="en"><surname>Shusharina</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наталья Николаевна Шушарина</p><p>236041, г. Калининград, ул. Александра Невского, д. 14</p></bio><bio xml:lang="en"><p>Natalya N. Shusharina</p><p>14 Aleksandr Nevsky Str., 236041 Kaliningrad</p></bio><email xlink:type="simple">nnshusharina@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Балтийский федеральный университет им. Иммануила Канта</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Imannuel Kant Baltic Federal University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>04</day><month>11</month><year>2025</year></pub-date><volume>21</volume><issue>5</issue><fpage>15</fpage><lpage>25</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Тынтерова А.М., Моисеева Е.М., Хоймов М.С., Шушарина Н.Н., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Тынтерова А.М., Моисеева Е.М., Хоймов М.С., Шушарина Н.Н.</copyright-holder><copyright-holder xml:lang="en">Tynterova A.M., Moiseeva E.M., Khoymov M.S., Shusharina N.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.reanimatology.com/rmt/article/view/2579">https://www.reanimatology.com/rmt/article/view/2579</self-uri><abstract><p>Цель исследования — выявить потенциальные предикторы функционального исхода (ФИ) у пациентов с подтипами ишемического инсульта (ИИ), не получавших реперфузионную терапию.</p><sec><title>Материалы и методы</title><p>Материалы и методы. В проспективное исследование включили 229 пациентов с диагнозом «ишемический инсульт», которых разделили на три группы в зависимости от подтипа ИИ: 1-я группа — 84 пациента с кардиоэмболическим ИИ; 2-я группа — 65 пациентов с атеротромботическим ИИ; 3-я группа — 80 пациентов с лакунарным ИИ. В качестве критериев ФИ рассматривали изменения значения mRS путем вычисления разницы между параметрами при поступлении и на 21-й день от развития ИИ — ∆mRS. С целью оптимизации работы модели машинного обучения (ML), выбрали бинарную классификацию ФИ на 21-й день от развития ИИ: показатель mRS ≥ 3 баллов соответствовал неблагоприятному нелетальному исходу, mRS = 0–2 балла — благоприятному ФИ. Анализировали взаимосвязь с ФИ (коэффициент корреляции, r) и предиктивную способность (ML (дерево решений), прирост информации, п. и.) 29-ти параметров: демографические; коморбидность; данные инструментальных методов исследования; NIHSS, BI, CDR; сывороточные концентраций цитокинов на 2-й день госпитализации.</p></sec><sec><title>Результаты</title><p>Результаты. Выявили значимые (p&lt;0,0001) предикторы неблагоприятного нелетального ФИ: в 1-й группе — женский пол (п. и. = 0,346), наличие повторного ИИ (п. и. = 0,248), сахарный диабет (п. и. = 0,442), концентрацию CXCL2 (п. и. = 0,306); во 2-й группе — степень ГИБВ (п.и. = 0,206), наличие сахарного диабета (п. и. = 0,340), содержание CCL2 (п. и. = 0,116), CCL3 (п. и. = 0,202) и CCL23 (п. и. = 0,101); в 3-й группе — возраст (п. и. = 0,106), ожирение 2–3-й степени (п. и. = 0,150), степень ГИБВ (п. и. = 0,300), содержание CXCL5 (п. и. = 0,143) и MIF (п. и. = 0,145). В качестве предикторов благоприятного ФИ (p&lt;0,0001) в 1-й группе выявили концентрации CCL25 (п. и. = 0, 108) и IL-6 (п. и. = 0,401); во 2-й группе — ожирение 1-й степени (п. и. = 0, 118) и концентрация TNF-α (п. и. = 0,211); в 3-й группе — наличие ГБ (п. и. = 0,113) и ожирение 1-й степени.</p></sec><sec><title>Заключение</title><p>Заключение. Результаты исследования продемонстрировали различия в структуре факторов, влияющих на ФИ в зависимости от патогенетического подтипа. Несмотря на определенную ценность полученных данных, для расширения возможностей прогнозирования исхода острого ИИ, требуется дальнейшее проведение исследований с целью подтверждения значимости выявленных маркеров.</p></sec></abstract><trans-abstract xml:lang="en"><p>The aim of the study was to identify potential predictors of functional outcome (FO) in patients with subtypes of ischemic stroke (IS) who did not receive reperfusion therapy.</p><sec><title>Materials and methods</title><p>Materials and methods. A prospective study included 229 patients with ischemic stroke divided . into three groups based on the IS subtype: Group 1 — 84 patients with cardioembolic IS; Group 2 — 65 patients with atherothrombotic IS; Group 3 — 80 patients with lacunar IS. Changes in the modified Rankin Scale (mRS) scores were considered as FO criteria calculated as the difference between the scores on admission and on the 21st day after IS onset — ∆mRS. In order to optimize the performance of the machine learning (ML) model, a binary FO approach was chosen for assessment on the 21st day after IS onset: mRS ≥ 3 scores corresponded to an unfavorable non-lethal outcome, and mRS = 0–2 scores corresponded to a favorable FO. We analyzed the interrelation with FO (correlation coefficient, r) and the predictive ability (ML (decision tree), information gain, i. g.) of 29 parameters, including demographic features; comorbidities; instrumental examination findings; NIHSS, BI, CDR scores; serum concentrations of cytokines on the 2nd day of hospital stay.</p></sec><sec><title>Results</title><p>Results. The following significant (P&lt;0.0001) predictors of unfavorable non-lethal FO were identified: female sex (i. g. = 0.346), recurrent IS (i. g = 0.248), diabetes mellitus (i. g. = 0.442), and CXCL2 concentration (i.g. = 0.306) in Group 1; WMHs severity (i. g. = 0.206), diabetes mellitus (i. g. = 0.340), content of CCL2 (i. g. = 0.116), CCL3 (i. g. = 0.202) and CCL23 (i. g. = 0.101) in Group 2; age (i. g. = 0.106), 2nd –3rd degree obesity (i. g. = 0.150), WMHs severity (i. g. = 0.300), CXCL5 content (i. g. = 0.143) and MIF (i. g. = 0.145) in Group 3. Concentrations of CCL25 (i. g. = 0.108) and IL-6 (i. g. = 0.401) were found as predictors of favorable FO (P&lt;0.0001) in Group 1; 1st degree obesity (i. g. = 0.118) and TNF-α concentration (i. g. = 0.211) in Group 2; arterial hypertension (AH) (i. g. = 0.113) and 1st degree obesity in Group 3.</p></sec><sec><title>Conclusion</title><p>Conclusion. Study results made evident the variances in combination of factors affecting FO, depending on IS pathogenetic subtype. Despite undoubtful value of the data obtained, further research is needed to expand the potentiality in predicting acute IS outcome and confirm the relevance of identified markers.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ишемический инсульт</kwd><kwd>острый период</kwd><kwd>функциональный исход</kwd><kwd>mRS</kwd><kwd>подтипы ишемического инсульта</kwd><kwd>прогностические маркеры</kwd></kwd-group><kwd-group xml:lang="en"><kwd>schemic stroke</kwd><kwd>acute phase</kwd><kwd>functional outcome</kwd><kwd>mRS</kwd><kwd>subtypes of ischemic stroke</kwd><kwd>prognostic markers</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Савелло А. В., Вознюк И. А., Бабичев К. Н., Кандыба Д. В., Шендеров С. В., Власенко С. В., Сараев Г. Б. Шкала прогнозирования раннего функционального исхода после внутрисосудистой тромбоэмболэктомии при каротидном ишемическом инсульте. Журнал неврологии и психиатрии им. С. С. Корсакова. 2021; 121 (6): 34–39. DOI: 10.17116/jnevro202112106134.</mixed-citation><mixed-citation xml:lang="en">Savello A. V., Voznyuk I. A., Babichev K. N., Kandyba D. V., Shenderov S. V., Vlasenko S. V., Saraev G. B. A prognosis scale for functional outcome at discharge after endovascular thrombectomy in the carotid artery territory. S.S. Korsakov Journal of Neurology and Psychiatry. 2021; 121 (6): 34–39. (in Russ.). DOI: 10.17116/jnevro202112106134.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Силкин В. В., Ершов В. И., Бурдаков В. В., Бирюкова Т. В., Бредихин А. Ю., Лозинская Т. Ю. Математическое моделирование тяжелого ишемического инсульта с полиорганной недостаточностью: ретроспективное наблюдательное исследование. Вестник интенсивной терапии им. А. И. Салтанова. 2023; 1: 91–100. DOI: 10.21320/1818-474X-2023-1-91-100.</mixed-citation><mixed-citation xml:lang="en">Silkin V. V., Ershov V. I., Burdakov V. V., Biryukova T. V., Bredikhin A.Yu., Lozinskaya T.Yu. Mathematical modeling of severe ischemic stroke with multiple organ failure: a retrospective observational study. Annals of Critical Care. 2023; 1: 91–100. (in Russ.). DOI: 10.21320/1818-474X-2023-1-91-100.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Manchi M. R., Venkatachalam A. M., Atem F. D., Stone S., Mathews A. A., Abraham A. M., Chavez A. A., et al. Effect of inpatient rehabilitation facility care on ninety day modified Rankin score in ischemic stroke patients. J Stroke Cerebrovasc Dis. 2023 Jun; 32 (6): 107109. DOI: 10.1016/j.jstrokecerebrovasdis.2023.107109. PMID: 37031503.</mixed-citation><mixed-citation xml:lang="en">Manchi M. R., Venkatachalam A. M., Atem F. D., Stone S., Mathews A. A., Abraham A. M., Chavez A. A., et al. Effect of inpatient rehabilitation facility care on ninety day modified Rankin score in ischemic stroke patients. J Stroke Cerebrovasc Dis. 2023 Jun; 32 (6): 107109. DOI: 10.1016/j.jstrokecerebrovasdis.2023.107109. PMID: 37031503.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Guzek Z., Dziubek W., Stefańska M., Kowalska J. Evaluation of the functional outcome and mobility of patients after stroke depending on their cognitive state. Sci Rep. 2024 Jan 17; 14 (1): 1515. DOI: 10.1038/s41598-024-52236-8. PMID: 38233519.</mixed-citation><mixed-citation xml:lang="en">Guzek Z., Dziubek W., Stefańska M., Kowalska J. Evaluation of the functional outcome and mobility of patients after stroke depending on their cognitive state. Sci Rep. 2024 Jan 17; 14 (1): 1515. DOI: 10.1038/s41598-024-52236-8. PMID: 38233519.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gardener H., Romano L. A., Smith E. E., Campo-Bustillo I., Khan Y., Tai S., Riley N., et al. Functional status at 30 and 90 days after mild ischaemic stroke. Stroke Vasc Neurol. 2022 Apr 26; 7 (5): 375–380. DOI: 10.1136/svn-2021-001333. PMID: 35474180.</mixed-citation><mixed-citation xml:lang="en">Gardener H., Romano L. A., Smith E. E., Campo-Bustillo I., Khan Y., Tai S., Riley N., et al. Functional status at 30 and 90 days after mild ischaemic stroke. Stroke Vasc Neurol. 2022 Apr 26; 7 (5): 375–380. DOI: 10.1136/svn-2021-001333. PMID: 35474180.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Новикова Л. Б., Акопян А. П., Латыпова Р. Ф. Анализ исхода острого периода ишемического инсульта. Анналы клинической и экспериментальной неврологии. 2022; 16 (4): 5–11. DOI: 10.54101/ACEN.2022.4.1.</mixed-citation><mixed-citation xml:lang="en">Novikova L. B., Akopyan A. P., Latypova R. F. Evaluation of the outcome in ischemic stroke acute period. Annals of Clinical and Experimental Neurology. 2022; 16 (4): 5–11. (In Russ.) DOI: 10.54101/ACEN.2022.4.1.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Pawluk H., Woźniak A, Grześk G., Kołodziejska R., Kozakiewicz M., Kopkowska E., Grzechowiak E., Kozera G. The Role of Selected Pro-Inflammatory Cytokines in Pathogenesis of Ischemic Stroke. Clin Interv Aging. 2020 Mar 23; 15: 469–484. DOI: 10.2147/CIA.S233909. PMID: 32273689.</mixed-citation><mixed-citation xml:lang="en">Pawluk H., Woźniak A, Grześk G., Kołodziejska R., Kozakiewicz M., Kopkowska E., Grzechowiak E., Kozera G. The Role of Selected Pro-Inflammatory Cytokines in Pathogenesis of Ischemic Stroke. Clin Interv Aging. 2020 Mar 23; 15: 469–484. DOI: 10.2147/CIA.S233909. PMID: 32273689.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Klimiec-Moskal E., Koceniak P., Weglarczyk K., Slowik A., Siedlar M., Dziedzic T. Circulating chemokines and short- and long-term outcomes after ischemic stroke. Mol Neurobiol. 2025 Jan; 62 (1): 421–428. DOI: 10.1007/s12035-024-04279-1. PMID: 38861234.</mixed-citation><mixed-citation xml:lang="en">Klimiec-Moskal E., Koceniak P., Weglarczyk K., Slowik A., Siedlar M., Dziedzic T. Circulating chemokines and short- and long-term outcomes after ischemic stroke. Mol Neurobiol. 2025 Jan; 62 (1): 421–428. DOI: 10.1007/s12035-024-04279-1. PMID: 38861234.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Голубев А. М. Модели ишемического инсульта (обзор). Общая реаниматология. 2020; 16 (1): 59–72. DOI: 10.15360/1813-9779-2020-1-59-72.</mixed-citation><mixed-citation xml:lang="en">Golubev A. M. Models of Ischemic Stroke (Review). General Reanimatology. 2020; 16 (1): 59–72. (In Russ.) DOI: 10.15360/1813-9779-2020-1-59-72.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Poomalai G., Prabhakar S., Sirala Jagadesh N. Functional Ability and Health Problems of Stroke Survivors: An Explorative Study. Cureus. 2023 Jan 4; 15 (1): e33375. DOI: 10.7759/cureus.33375. PMID: 36751244.</mixed-citation><mixed-citation xml:lang="en">Poomalai G., Prabhakar S., Sirala Jagadesh N. Functional Ability and Health Problems of Stroke Survivors: An Explorative Study. Cureus. 2023 Jan 4; 15 (1): e33375. DOI: 10.7759/cureus.33375. PMID: 36751244.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hu Y., Jiang X., Li Y., Yang C., Ma M., Fang J., He L. Endovascular treatment with or without intravenous thrombolysis for acute ischemic stroke due to tandem occlusion: a systematic review and meta-analysis. J Am Heart Assoc. 2024 Sep 3; 13 (17): e034829. DOI: 10.1161/JAHA.124.034829. PMID: 39206729.</mixed-citation><mixed-citation xml:lang="en">Hu Y., Jiang X., Li Y., Yang C., Ma M., Fang J., He L. Endovascular treatment with or without intravenous thrombolysis for acute ischemic stroke due to tandem occlusion: a systematic review and meta-analysis. J Am Heart Assoc. 2024 Sep 3; 13 (17): e034829. DOI: 10.1161/JAHA.124.034829. PMID: 39206729.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Максимова М. Ю., Гулевская Т. С. Лакунарный инсульт. Журнал неврологии и психиатрии им. С. С. Корсакова. 2019; 119 (8 вып. 2): 13–27. DOI: 10.17116/jnevro201911908213.</mixed-citation><mixed-citation xml:lang="en">Maksimova M. Yu., Gulevskaya T. S. Lacunar stroke. S. S.Korsakov Journal of Neurology and Psychiatry. 2019; 119 (8 vyp. 2): 13–27. (In Russ.). DOI: 10.17116/jnevro201911908213.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lau L. H., Lew J., Borschmann K., Thijs V., Ekinci E. I. Prevalence of diabetes and its effects on stroke outcomes: A meta-analysis and literature review. J Diabetes Investig. 2019 May; 10 (3): 780–792. DOI: 10.1111/jdi.12932. PMID: 30220102.</mixed-citation><mixed-citation xml:lang="en">Lau L. H., Lew J., Borschmann K., Thijs V., Ekinci E. I. Prevalence of diabetes and its effects on stroke outcomes: A meta-analysis and literature review. J Diabetes Investig. 2019 May; 10 (3): 780–792. DOI: 10.1111/jdi.12932. PMID: 30220102.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Воронина В. П., Загребельный А. В., Лукина Ю. В., Кутишенко Н. П., Дмитриева Н. А., Лерман О. В., Лукьянов М. М. c соавт. Особенности течения мозгового инсульта у больных сахарным диабетом по данным регистра РЕГИОН-М. Кардиоваскулярная терапия и профилактика. 2019; 18 (5): 60–65. https://doi.org/10.15829/1728-8800-2019-5-60-65.</mixed-citation><mixed-citation xml:lang="en">Voronina V. P., Zagrebelnyi A. V., Lukina Yu.V., Kutishenko N. P., Dmitrieva N. A., Lerman O. V., Lukyanov M. M., et al. Features of cerebral stroke course in patients with diabetes mellitus according to the REGION-M register. Cardiovascular Therapy and Prevention. 2019; 18 (5): 60–65 (In Russ.). DOI: 10.15829/1728-8800-2019-5-60-65.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Miwa K., Nakai M., Yoshimura S., Sasahara Y., Wada S., Koge J., Ishigami A., et al. Clinical impact of body mass index on outcomes of ischemic and hemorrhagic strokes. Int J Stroke. 2024 Oct; 19 (8): 907–915. DOI: 10.1177/17474930241249370. PMID: 38651751.</mixed-citation><mixed-citation xml:lang="en">Miwa K., Nakai M., Yoshimura S., Sasahara Y., Wada S., Koge J., Ishigami A., et al. Clinical impact of body mass index on outcomes of ischemic and hemorrhagic strokes. Int J Stroke. 2024 Oct; 19 (8): 907–915. DOI: 10.1177/17474930241249370. PMID: 38651751.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Захарычева Т. А., Широкова А. С., Поляков А. Г., Яицкая Е. О., Чекурина С. Л. Лакунарные инсульты. Клинические наблюдения. Регионарное кровообращение и микроциркуляция. 2022; 21 (4): 94–101. https://doi.org/10.24884/1682-6655-2022-21-4-94-101.</mixed-citation><mixed-citation xml:lang="en">Zakharycheva T. A., Shirokova A. S., Polyakov A. G., Yaitskaya E. O., Chekurina S. L. Lacunary stroke. Clinical cases. Regional blood circulation and microcirculation. 2022; 21 (4): 94–101. (In Russ.). DOI: 10.24884/1682-6655-2022-21-4-94-101.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Миклишанская С. В., Мазур Н. А., Соломасова Л. В., Чигинева В. В. «Парадокс ожирения» и степень его доказанности. Терапевтический архив. 2020; 92 (4): 84–90. DOI: 10.26442/00403660.2020.04.000421.</mixed-citation><mixed-citation xml:lang="en">Miklisanskaya S. V., Mazur N. A., Solomasova L. V., Chigineva V. V. The «obesity paradox» and its degree of proof. Therapeutic Archive. 2020; 92 (4): 84–90. (In Russ.)] DOI: 10.26442/00403660.2020.04.000421.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Антонова К. В., Танашян М. М., Раскуражев А. А., Спрышков Н. Е., Панина А. А., Лагода О. В., Аметов А. С. с соавт. Ожирение и нервная система. Ожирение и метаболизм. 2024; 21 (1): 68–78. DOI: 10.14341/omet13019.</mixed-citation><mixed-citation xml:lang="en">Antonova K. V., Tanashyan M. M., Raskurazhev A. A., Spryshkov N. E., Panina A. A., Lagoda O. V., Ametov A. S., et al. Obesity and the nervous system. Obesity and metabolism. 2024; 21 (1): 68–78. DOI: 10.14341/omet13019.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Horn J. W., Feng T., Mørkedal B., Strand L. B., Horn J., Mukamal K., Janszky I. Obesity and Risk for First Ischemic Stroke Depends on Metabolic Syndrome: The HUNT Study. Stroke. 2021 Nov; 52 (11): 3555–3561. DOI: 10.1161/STROKEAHA.120.033016. PMID: 34281375.</mixed-citation><mixed-citation xml:lang="en">Horn J. W., Feng T., Mørkedal B., Strand L. B., Horn J., Mukamal K., Janszky I. Obesity and Risk for First Ischemic Stroke Depends on Metabolic Syndrome: The HUNT Study. Stroke. 2021 Nov; 52 (11): 3555–3561. DOI: 10.1161/STROKEAHA.120.033016. PMID: 34281375.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ruan H., Ran X., Li SS, Zhang Q. Dyslipidemia versus obesity as predictors of ischemic stroke prognosis: a multi-center study in China. Lipids Health Dis. 2024 Mar 9; 23 (1): 72. DOI: 10.1186/s12944-024-02061-9. PMID: 38461258.</mixed-citation><mixed-citation xml:lang="en">Ruan H., Ran X., Li SS, Zhang Q. Dyslipidemia versus obesity as predictors of ischemic stroke prognosis: a multi-center study in China. Lipids Health Dis. 2024 Mar 9; 23 (1): 72. DOI: 10.1186/s12944-024-02061-9. PMID: 38461258.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Dahl S., Hjalmarsson C., Andersson B. Sex differences in risk factors, treatment, and prognosis in acute stroke. Womens Health (Lond). 2020 Jan–Dec; 16: 1745506520952039. DOI: 10.1177/1745506520952039. PMID: 32997605</mixed-citation><mixed-citation xml:lang="en">Dahl S., Hjalmarsson C., Andersson B. Sex differences in risk factors, treatment, and prognosis in acute stroke. Womens Health (Lond). 2020 Jan–Dec; 16: 1745506520952039. DOI: 10.1177/1745506520952039. PMID: 32997605</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ko D., Rahman F., Schnabel R. B., Yin X., Benjamin E. J., Christophersen I. E. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol. 2016 Jun; 13 (6): 321–32. DOI: 10.1038/nrcardio.2016.45. PMID: 27053455.</mixed-citation><mixed-citation xml:lang="en">Ko D., Rahman F., Schnabel R. B., Yin X., Benjamin E. J., Christophersen I. E. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol. 2016 Jun; 13 (6): 321–32. DOI: 10.1038/nrcardio.2016.45. PMID: 27053455.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Santamarнa M., López-Dequidt I., López-Loureiro I., RodríguezPérez M., Hervella P., Sobrino T., Campos F. et al. Influence of Sex on Stroke Prognosis: A Demographic, Clinical, and Molecular Analysis. Front Neurol. 2019 Apr 17; 10: 388. DOI: 10.3389/fneur.2019.00388. PMID: 31057479.</mixed-citation><mixed-citation xml:lang="en">Santamarнa M., López-Dequidt I., López-Loureiro I., RodríguezPérez M., Hervella P., Sobrino T., Campos F. et al. Influence of Sex on Stroke Prognosis: A Demographic, Clinical, and Molecular Analysis. Front Neurol. 2019 Apr 17; 10: 388. DOI: 10.3389/fneur.2019.00388. PMID: 31057479.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Мхитарян Э. А., Фатеева В. В. Возраст-зависимая церебральная микроангиопатия, ассоциированная с сосудистыми факторами риска: как распознать на гериатрическом приеме. Российский журнал гериатрической медицины. 2024; (1): 49–55. DOI: 10.37586/2686-8636-1-2024-49-55.</mixed-citation><mixed-citation xml:lang="en">Mkhitaryan E. A., Fateeva V. V. Age-Dependent Cerebral Microangiopathy Associated with Vascular Risk Factors: How to Recognize the Signs? Russian Journal of Geriatric Medicine. 2024; (1): 49–55. (In Russ.) DOI: 10.37586/2686-8636-1-2024-49-55.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Lu X., Wang Z., Ye D., Feng Y., Liu M., Xu Y., Wang M., et al. The Role of CXC Chemokines in Cardiovascular Diseases. Front Pharmacol. 2022 May 20; 12: 765768. DOI: 10.3389/fphar.2021.765768. PMID: 35668739.</mixed-citation><mixed-citation xml:lang="en">Lu X., Wang Z., Ye D., Feng Y., Liu M., Xu Y., Wang M., et al. The Role of CXC Chemokines in Cardiovascular Diseases. Front Pharmacol. 2022 May 20; 12: 765768. DOI: 10.3389/fphar.2021.765768. PMID: 35668739.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y. L., Cao H. J., Han X., Teng F., Chen C., Yang J., Yan X., et al. Chemokine Receptor C. X.CR-2 Initiates Atrial Fibrillation by Triggering Monocyte Mobilization in Mice. Hypertension. 2020 Aug; 76 (2): 381–392. DOI: 10.1161/HYPERTENSIONAHA.120.14698. PMID: 32639881.</mixed-citation><mixed-citation xml:lang="en">Zhang Y. L., Cao H. J., Han X., Teng F., Chen C., Yang J., Yan X., et al. Chemokine Receptor C. X.CR-2 Initiates Atrial Fibrillation by Triggering Monocyte Mobilization in Mice. Hypertension. 2020 Aug; 76 (2): 381–392. DOI: 10.1161/HYPERTENSIONAHA.120.14698. PMID: 32639881.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang R. M., McNerney K. P., Riek A. E., Bernal-Mizrachi C. Immunity and Hypertension. Acta Physiol. (Oxf) 2021; 231: e13487. DOI: 10.1111/apha.13487. PMID: 32359222.</mixed-citation><mixed-citation xml:lang="en">Zhang R. M., McNerney K. P., Riek A. E., Bernal-Mizrachi C. Immunity and Hypertension. Acta Physiol. (Oxf) 2021; 231: e13487. DOI: 10.1111/apha.13487. PMID: 32359222.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Korbecki J., Maruszewska A., Bosiacki M., Chlubek D., Baranowska-Bosiacka I. The Potential Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Cardiovascular System, Respiratory System and Skin. Int J Mol Sci. 2022 Dec 22; 24 (1): 205. DOI: 10.3390/ijms24010205. PMID: 36613652.</mixed-citation><mixed-citation xml:lang="en">Korbecki J., Maruszewska A., Bosiacki M., Chlubek D., BaranowskaBosiacka I. The Potential Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Cardiovascular System, Respiratory System and Skin. Int J Mol Sci. 2022 Dec 22; 24 (1): 205. DOI: 10.3390/ijms24010205. PMID: 36613652.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Yan Y., Thakur M., van der Vorst E. P. C., Weber C., Döring Y. Targeting the chemokine network in atherosclerosis. Atherosclerosis. 2021 Aug; 330: 95–106. DOI: 10.1016/j.atherosclerosis.2021.06.912. PMID: 34247863.</mixed-citation><mixed-citation xml:lang="en">Yan Y., Thakur M., van der Vorst E. P. C., Weber C., Döring Y. Targeting the chemokine network in atherosclerosis. Atherosclerosis. 2021 Aug; 330: 95–106. DOI: 10.1016/j.atherosclerosis.2021.06.912. PMID: 34247863.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Kim C. S., Kang J. H., Cho H. R., Blankenship T. N., Erickson K. L., Kawada T., Yu R. Potential involvement of CCL23 in atherosclerotic lesion formation/progression by the enhancement of chemotaxis, adhesion molecule expression, and MMP-2 release from monocytes. Inflamm Res. 2011 Sep; 60 (9): 889–95. DOI: 10.1007/s00011-011-0350-5. PMID: 21656154.</mixed-citation><mixed-citation xml:lang="en">Kim C. S., Kang J. H., Cho H. R., Blankenship T. N., Erickson K. L., Kawada T., Yu R. Potential involvement of CCL23 in atherosclerotic lesion formation/progression by the enhancement of chemotaxis, adhesion molecule expression, and MMP-2 release from monocytes. Inflamm Res. 2011 Sep; 60 (9): 889–95. DOI: 10.1007/s00011-011-0350-5. PMID: 21656154.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Tsioufis P., Theofilis P., Tsioufis K., Tousoulis D. The impact of cytokines in coronary atherosclerotic plaque: current therapeutic approaches. Int J Mol Sci. 2022 Dec 14; 23 (24): 15937. DOI: 10.3390/ijms232415937. PMID: 36555579.</mixed-citation><mixed-citation xml:lang="en">Tsioufis P., Theofilis P., Tsioufis K., Tousoulis D. The impact of cytokines in coronary atherosclerotic plaque: current therapeutic approaches. Int J Mol Sci. 2022 Dec 14; 23 (24): 15937. DOI: 10.3390/ijms232415937. PMID: 36555579.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Wu X., Sun M., Yang Z., Lu C., Wang Q., Wang H., Deng C., Liu Y., Yang Y. The Roles of CCR9/CCL25 in Inflammation and Inflammation-Associated Diseases. Front Cell Dev Biol. 2021 Aug 19; 9: 686548. DOI: 10.3389/fcell.2021.686548. PMID: 34490243</mixed-citation><mixed-citation xml:lang="en">Wu X., Sun M., Yang Z., Lu C., Wang Q., Wang H., Deng C., Liu Y., Yang Y. The Roles of CCR9/CCL25 in Inflammation and Inflammation-Associated Diseases. Front Cell Dev Biol. 2021 Aug 19; 9: 686548. DOI: 10.3389/fcell.2021.686548. PMID: 34490243</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Kummer K. K., Zeidler M., Kalpachidou T., Kress M. Role of IL-6 in the regulation of neuronal development, survival and function. Cytokine. 2021 Aug; 144: 155582. DOI: 10.1016/j.cyto.2021.155582. PMID: 34058569.</mixed-citation><mixed-citation xml:lang="en">Kummer K. K., Zeidler M., Kalpachidou T., Kress M. Role of IL-6 in the regulation of neuronal development, survival and function. Cytokine. 2021 Aug; 144: 155582. DOI: 10.1016/j.cyto.2021.155582. PMID: 34058569.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Xue Y., Zeng X., Tu W. J., Zhao J. Tumor Necrosis Factor-α: The Next Marker of Stroke. Dis Markers. 2022 Feb 27; 2022: 2395269. DOI: 10.1155/2022/2395269. PMID: 35265224.</mixed-citation><mixed-citation xml:lang="en">Xue Y., Zeng X., Tu W. J., Zhao J. Tumor Necrosis Factor-α: The Next Marker of Stroke. Dis Markers. 2022 Feb 27; 2022: 2395269. DOI: 10.1155/2022/2395269. PMID: 35265224.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Cao Q., Chen J., Zhang Z., Shu S., Qian Y., Yang L., Xu L., et al. Astrocytic CXCL5 hinders microglial phagocytosis of myelin debris and aggravates white matter injury in chronic cerebral ischemia. J Neuroinflammation. 2023 May 3; 20 (1): 105. DOI: 10.1186/s12974-023-02780-3. PMID: 37138312</mixed-citation><mixed-citation xml:lang="en">Cao Q., Chen J., Zhang Z., Shu S., Qian Y., Yang L., Xu L., et al. Astrocytic CXCL5 hinders microglial phagocytosis of myelin debris and aggravates white matter injury in chronic cerebral ischemia. J Neuroinflammation. 2023 May 3; 20 (1): 105. DOI: 10.1186/s12974-023-02780-3. PMID: 37138312</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao G., Kumar R., Komuro Y., Burguet J., Kakarla V., Azizkhanian I., Sheth S. A., et al. IL-17/CXCL5 signaling within the oligovascular niche mediates human and mouse white matter injury. Cell Rep. 2022 Dec 20; 41 (12): 111848. DOI: 10.1016/j.celrep.2022.111848. PMID: 36543124</mixed-citation><mixed-citation xml:lang="en">Xiao G., Kumar R., Komuro Y., Burguet J., Kakarla V., Azizkhanian I., Sheth S. A., et al. IL-17/CXCL5 signaling within the oligovascular niche mediates human and mouse white matter injury. Cell Rep. 2022 Dec 20; 41 (12): 111848. DOI: 10.1016/j.celrep.2022.111848. PMID: 36543124</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Chen C., Chang T. T., Chen J. W. Mechanistic role of CXCL5 in cardiovascular disease, diabetes mellitus, and kidney disease. Life Sci. 2023 Oct 1; 330: 122018. DOI: 10.1016/j.lfs.2023.122018. PMID: 37567498.</mixed-citation><mixed-citation xml:lang="en">Chen C., Chang T. T., Chen J. W. Mechanistic role of CXCL5 in cardiovascular disease, diabetes mellitus, and kidney disease. Life Sci. 2023 Oct 1; 330: 122018. DOI: 10.1016/j.lfs.2023.122018. PMID: 37567498.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Chen C., Lin L. Y., Wu Y. W., Chen J. W., Chang T. T. CXCL5 inhibition improves kidney function by protecting renal tubular epithelial cells in diabetic kidney disease. Clin Immunol. 2024 Nov; 268: 110369. DOI: 10.1016/j.clim.2024.110369. PMID: 39326648.</mixed-citation><mixed-citation xml:lang="en">Chen C., Lin L. Y., Wu Y. W., Chen J. W., Chang T. T. CXCL5 inhibition improves kidney function by protecting renal tubular epithelial cells in diabetic kidney disease. Clin Immunol. 2024 Nov; 268: 110369. DOI: 10.1016/j.clim.2024.110369. PMID: 39326648.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y., Yu Z., Ye N., Zhen X. Macrophage migration inhibitory factor (MIF) in CNS diseases: Functional regulation and potential therapeutic indication. Fundam Res. 2023 May 30; 4 (6): 1375–1388. DOI: 10.1016/j.fmre.2023.05.008. PMID: 39734533</mixed-citation><mixed-citation xml:lang="en">Zhang Y., Yu Z., Ye N., Zhen X. Macrophage migration inhibitory factor (MIF) in CNS diseases: Functional regulation and potential therapeutic indication. Fundam Res. 2023 May 30; 4 (6): 1375–1388. DOI: 10.1016/j.fmre.2023.05.008. PMID: 39734533</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y. S., Chen W., Liu S., Zhang Y. Y., Li X. H. Serum macrophage migration inhibitory factor levels are associated with infarct volumes and long-term outcomes in patients with acute ischemic stroke. Int J Neurosci. 2017 Jun; 127 (6): 539–546. DOI: 10.1080/00207454.2016.1211648. PMID: 27402018.</mixed-citation><mixed-citation xml:lang="en">Li Y. S., Chen W., Liu S., Zhang Y. Y., Li X. H. Serum macrophage migration inhibitory factor levels are associated with infarct volumes and long-term outcomes in patients with acute ischemic stroke. Int J Neurosci. 2017 Jun; 127 (6): 539–546. DOI: 10.1080/00207454.2016.1211648. PMID: 27402018.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao J., Wang X., Yu M., Zhang S., Li Q., Liu H., Zhang J., et al. The relevance of serum macrophage migration inhibitory factor level and executive function in patients with white matter hyperintensity in cerebral small vessel disease. Brain Sci. 2023 Apr 5; 13 (4): 616. DOI: 10.3390/brainsci13040616. PMID: 37190581</mixed-citation><mixed-citation xml:lang="en">Zhao J., Wang X., Yu M., Zhang S., Li Q., Liu H., Zhang J., et al. The relevance of serum macrophage migration inhibitory factor level and executive function in patients with white matter hyperintensity in cerebral small vessel disease. Brain Sci. 2023 Apr 5; 13 (4): 616. DOI: 10.3390/brainsci13040616. PMID: 37190581</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Chen L., Li L., Cui D., Huang Y., Tong H., Zabihi H., Wang S., et al. Extracellular macrophage migration inhibitory factor (MIF) downregulates adipose hormone-sensitive lipase (HSL) and contributes to obesity. Mol Metab. 2024 Jan; 79: 101834. DOI: 10.1016/j.molmet.2023.101834. PMID: 37935315</mixed-citation><mixed-citation xml:lang="en">Chen L., Li L., Cui D., Huang Y., Tong H., Zabihi H., Wang S., et al. Extracellular macrophage migration inhibitory factor (MIF) downregulates adipose hormone-sensitive lipase (HSL) and contributes to obesity. Mol Metab. 2024 Jan; 79: 101834. DOI: 10.1016/j.molmet.2023.101834. PMID: 37935315</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Cui N., Li H., Dun Y., Ripley-Gonzalez J. W., You B., Li D., Liu Y., et al. Exercise inhibits JNK pathway activation and lipotoxicity via macrophage migration inhibitory factor in nonalcoholic fatty liver disease. Front Endocrinol (Lausanne). 2022 Sep 6; 13: 961231. DOI: 10.3389/fendo.2022.961231. PMID: 36147562</mixed-citation><mixed-citation xml:lang="en">Cui N., Li H., Dun Y., Ripley-Gonzalez J. W., You B., Li D., Liu Y., et al. Exercise inhibits JNK pathway activation and lipotoxicity via macrophage migration inhibitory factor in nonalcoholic fatty liver disease. Front Endocrinol (Lausanne). 2022 Sep 6; 13: 961231. DOI: 10.3389/fendo.2022.961231. PMID: 36147562</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng Q., McKeown S. J., Santos L., Santiago F. S., Khachigian L. M., Morand E. F., Hickey M. J. Macrophage migration inhibitory factor increases leukocyte-endothelial interactions in human endothelial cells via promotion of expression of adhesion molecules. J Immunol. 2010 Jul 15; 185 (2): 1238–47. DOI: 10.4049/jimmunol.0904104. PMID: 20554956.</mixed-citation><mixed-citation xml:lang="en">Cheng Q., McKeown S. J., Santos L., Santiago F. S., Khachigian L. M., Morand E. F., Hickey M. J. Macrophage migration inhibitory factor increases leukocyte-endothelial interactions in human endothelial cells via promotion of expression of adhesion molecules. J Immunol. 2010 Jul 15; 185 (2): 1238–47. DOI: 10.4049/jimmunol.0904104. PMID: 20554956.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
